Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves reported option and warrant exercises followed by stock sales. On January 15, 2026, she exercised an employee stock option for 3,500 shares of common stock at $6.84 per share and an employee warrant for another 3,500 shares at $7.8 per share.
That same day, she sold 4,381 shares of common stock at a weighted average price of $31.5626 and 2,619 shares at a weighted average price of $32.237, all under a Rule 10b5-1 trading plan entered into on September 19, 2025. After these transactions, she directly owned 1,518 shares of common stock, as well as 221,563 employee stock options and 192,992 employee warrants.
Oruka Therapeutics, Inc. director Christopher Martin reported receiving stock options to purchase 35,000 shares of the company’s common stock at an exercise price of $30.21 per share on December 11, 2025.
The options expire on December 10, 2035 and vest in equal monthly installments, with 1/36 of the underlying shares vesting each month starting December 11, 2025. After this grant, he beneficially owns options for 35,000 shares, held directly.
Oruka Therapeutics, Inc. director Christopher Martin has filed an initial beneficial ownership report indicating that he does not beneficially own any of the company’s securities. The report, dated 12/11/2025, is filed by a single reporting person and confirms that no non-derivative or derivative securities of Oruka Therapeutics are beneficially owned.
Oruka Therapeutics, Inc. reported that director Cameron Turtle resigned from its Board of Directors on December 11, 2025. The company stated that his resignation was not due to any disagreement over Oruka’s operations, policies, or practices.
On the same day, the board elected Christopher Martin as a Class II director, with a term ending at the 2026 annual meeting of stockholders, and named him Chair of the Compensation Committee and a member of the Audit Committee. As a non-employee director, he received a stock option for 35,000 shares of Oruka common stock vesting in 36 equal monthly installments and is eligible for annual cash retainers of $40,000 for board service, $12,000 for chairing the Compensation Committee, and $7,500 for Audit Committee service. The board determined he is independent under SEC and Nasdaq standards and reported no related-party transactions.
Oruka Therapeutics reported a third‑quarter net loss of $30.277 million as it advanced clinical programs in psoriasis and other I&I indications. Operating expenses were $34.105 million, driven by $28.988 million in R&D and $5.117 million in G&A. Interest income of $3.832 million partially offset expenses. Basic and diluted net loss per common share was $0.55.
Liquidity strengthened: as of September 30, 2025, cash, cash equivalents, and marketable securities totaled $500.9 million. Management expects this balance to fund operating plans for at least twelve months from issuance of the financial statements.
Financing activity included a 2025 PIPE of 10,933,405 common shares at $15.00 and 1,066,666 pre‑funded warrants at $14.999, for net proceeds of approximately $169.6 million. On October 3, 2025, the company established an ATM program permitting sales of up to $200.0 million of common stock. Program spend included milestone expenses, such as $3.0 million for ORKA‑001 upon first dosing in a Phase 2 trial and earlier‑year milestones for ORKA‑002.
Oruka Therapeutics, Inc. (ORKA) filed a prospectus to register up to 39,425,806 shares of common stock for resale by selling stockholders. This is a secondary offering; the company is not selling shares and will not receive proceeds from stockholder sales. The filing states the company will receive only the nominal cash exercise price if holders exercise pre-funded warrants for cash.
The registered shares include 7,083,000 September 2024 Private Placement Common Shares (including shares issued upon Series A Preferred conversion in November 2024), 680,000 shares issuable upon exercise of September 2024 pre-funded warrants, 10,933,405 September 2025 Private Placement Common Shares, 1,066,666 shares issuable upon exercise of September 2025 pre-funded warrants, and 19,662,735 Additional Fairmount Holdings, which include 2,936,922 common shares, 5,297,664 pre-funded warrant shares, and 11,428,149 shares issuable upon conversion of 137,138 shares of Series B Preferred Stock.
Shares outstanding were 48,384,150 as of September 19, 2025. The company’s common stock trades on Nasdaq as “ORKA,” and the last reported sale price was $19.18 per share on October 2, 2025.
Oruka Therapeutics (ORKA) launched an at-the-market offering of up to $200,000,000 of common stock to be sold from time to time through TD Cowen as agent or principal, pursuant to a Rule 424(b)(5) prospectus. Sales may occur on Nasdaq or by other permitted methods under Rule 415(a)(4). TD Cowen’s compensation is up to 3.0% of the gross sales price, and it will be deemed an underwriter for these transactions.
The company intends to use net proceeds for general corporate purposes, including research and development and working capital. As an illustration in the prospectus, at a price of $19.18 per share, $200.0 million of sales would equal 10,427,528 shares, implying up to 47,878,273 shares outstanding after the offering; actual results will vary with market prices and timing. ORKA’s last reported sale price on Nasdaq was $19.18 per share on October 2, 2025. Shares outstanding were 37,450,745 as of June 30, 2025.
Oruka Therapeutics (ORKA) filed Amendment No. 1 to a resale registration statement covering up to 39,425,806 shares of Common Stock. The prospectus registers shares for potential resale by selling stockholders from prior financings, including (i) 7,083,000 September 2024 Private Placement Common Shares, (ii) 680,000 shares issuable upon exercise of September 2024 pre‑funded warrants, (iii) 10,933,405 September 2025 Private Placement Common Shares, (iv) 1,066,666 shares issuable upon exercise of September 2025 pre‑funded warrants, and (v) 19,662,735 shares tied to Additional Fairmount Holdings, including shares issuable upon conversion of Series B Preferred Stock.
The company is not selling any shares in this registration and will not receive proceeds from stockholder resales; it would receive only the nominal cash exercise price if pre‑funded warrants are exercised for cash.
Selling stockholders may sell on Nasdaq under “ORKA,” in negotiated transactions, or by other permitted methods described in the plan of distribution. As context, shares outstanding were 48,384,150 as of September 19, 2025, and the Resale Shares represent approximately 59% of outstanding assuming warrant exercises and Series B conversions.
Oruka Therapeutics, Inc. filed Amendment No. 1 to its Form S‑3 shelf registration, adding Rule 473(b) language so the registration becomes automatically effective 20 days after this amendment. The shelf allows Oruka to offer, from time to time, up to $500,000,000 of common stock, preferred stock, depositary shares, and warrants, with specific terms to be set in future supplements.
A separate prospectus establishes an at‑the‑market program with TD Securities (USA) LLC (TD Cowen) for up to $200,000,000 of common stock, which is included within the $500,000,000 shelf. Sales may occur on Nasdaq or other permitted markets, including block trades, with TD Cowen earning up to a 3.0% commission. Oruka states it intends to use proceeds for general corporate purposes, including research and development and working capital.
As context, the company’s common stock trades on Nasdaq as “ORKA.” The ATM and any other offerings may proceed only after effectiveness and will be detailed in future prospectus supplements.
Oruka Therapeutics filed a shelf registration that includes a base prospectus for up to $500,000,000 of securities and a sales agreement prospectus for up to $200,000,000 of common stock to be sold at-the-market through TD Securities (USA) LLC. The company may sell common stock, preferred stock, depositary shares and warrants and intends to use net proceeds for general corporate purposes, including research and development and working capital. The prospectus discloses anti-takeover provisions in the charter and bylaws (staggered board, director removal only for cause, advance notice for nominations) and authority to issue 5,000,000 shares of preferred stock. The filing lists convertible and exercisable instruments, including 11,428,149 shares issuable on conversion of Series B preferred, 6,202,207 pre-funded warrant shares, and 10,933,405 shares issued in the 2025 PIPE Financing, and assumes up to 47,878,273 shares outstanding after a sample sale at $19.18 per share.